Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest	$ (17,892)	$ (29,101)	$ (40,106)	$ (48,734)
Net loss attributable to noncontrolling interest	3,355	3,576	7,638	6,337
Net loss - as reported, attributable to PAVmed Inc.	(14,537)	(25,525)	(32,468)	(42,397)
Series B Convertible Preferred Stock dividends – earned	(75)	(70)	(149)	(138)
Net loss attributable to PAVmed Inc. common stockholders	$ (14,612)	$ (25,595)	$ (32,617)	$ (42,535)
Weighted average common shares outstanding, basic	104,349,822	86,957,352	100,742,530	86,689,857
Weighted average common shares outstanding, diluted	104,349,822	86,957,352	100,742,530	86,689,857
Net loss - as reported, attributable to PAVmed Inc, basic	$ (0.14)	$ (0.29)	$ (0.32)	$ (0.49)
Net loss - as reported, attributable to PAVmed Inc, diluted	(0.14)	(0.29)	(0.32)	(0.49)
Net loss attributable to PAVmed Inc. common stockholders, basic	(0.14)	(0.29)	(0.32)	(0.49)
Net loss attributable to PAVmed Inc. common stockholders, diluted	$ (0.14)	$ (0.29)	$ (0.32)	$ (0.49)